Press coverage about Soligenix (NASDAQ:SNGX) has trended positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Soligenix earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.6277718439317 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several research firms have recently weighed in on SNGX. Maxim Group set a $5.00 price objective on shares of Soligenix and gave the company a “buy” rating in a research note on Thursday, March 15th. HC Wainwright set a $3.00 price objective on shares of Soligenix and gave the company a “hold” rating in a research note on Friday, March 16th.
SNGX stock traded down $0.05 during midday trading on Friday, reaching $1.71. 12,165 shares of the company’s stock traded hands, compared to its average volume of 68,412. The firm has a market capitalization of $15.38, a PE ratio of -1.24 and a beta of 0.54. Soligenix has a 52 week low of $1.60 and a 52 week high of $4.40.
ILLEGAL ACTIVITY NOTICE: “Soligenix (NASDAQ:SNGX) Given Coverage Optimism Rating of 0.26” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://weekherald.com/2018/04/21/soligenix-sngx-given-news-sentiment-rating-of-0-26.html.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.